Skip to the content
Please enable JavaScript in your browser to complete this form.
Evaluation Form
Your feedback is important to us and will help us improve future meetings. We appreciate you taking a moment to complete this form.
Full name
*
1. Please rate the following questions:
To what extent do you agree/disagree that andexanet alfa should be implemented into your institutional protocol to optimise patient outcomes?
*
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Strongly agree
Item #1 Strongly agree
Agree
Item #1 Agree
Neutral
Item #1 Neutral
Disagree
Item #1 Disagree
Strongly disagree
Item #1 Strongly disagree
The date, time and duration of the meeting were convenient to my schedule
*
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Strongly agree
Item #1 Strongly agree
Agree
Item #1 Agree
Neutral
Item #1 Neutral
Disagree
Item #1 Disagree
Strongly disagree
Item #1 Strongly disagree
The overall preparation and delivery of the meeting were well organised
*
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Strongly agree
Item #1 Strongly agree
Agree
Item #1 Agree
Neutral
Item #1 Neutral
Disagree
Item #1 Disagree
Strongly disagree
Item #1 Strongly disagree
2. What other key considerations should be taken into account when developing effective patient criteria for andexanet alfa use in Hong Kong?
*
3. Did the meeting include relevant discussions points in your opinion?
*
Yes
No
3. No, Please expand
*
4. Do you have any additional feedback/comments?
*
Yes
No
4. Yes, Please expand
*
Submit
HK-10348 | May 2024